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Abstract 
This report briefly discusses a case of retroperitoneal Castleman’s disease in a 52 year old post-
menopausal woman with renal cell carcinoma. 
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Introduction 
Castleman’s disease is a rare, benign, lymphoproliferative disorder first described in 1954 that 
affects less than 200,000 people in the United States.1 While most cases involve the thorax, 15% 
of cases affect the abdomen or pelvis.2. Castleman’s disease is subdivided into two 
histopathological subtypes: hyaline-vascular variant or plasma cell variant.1 The hyaline-vascular 
variant is associated with abnormal lymphoid follicular hyperplasia and increased interfollicular 
vascularity while the plasma cell variant is distinguished by sheets of mature plasma cells on 
histology.3  
Castleman’s disease is further divided clinically into unicentric or multicentric disease. 
Unicentric, or localized disease, is typically asymptomatic and has well circumscribed lesions 
with moderate to intense enhancement on imaging. Multicentric disease typically presents with 
systemic systems such as fever, night sweats, peripheral lymphadenopathy, or 
hepatosplenomegaly, and is often associated with human immunodeficiency virus (HIV) or 
human herpes virus-8 (HHV-8) infection, and is harder to distinguish from lymphoproliferative 
disorders.1,3 In localized disease, 85- 90% of cases are hyaline-vascular variant.1 Most are found 
incidentally on imaging as patients are asymptomatic or have few symptoms with vague 
complaints.3 Radiological appearance is often nonspecific, so diagnosis must be made via biopsy 
or surgical resection.4 We report a case of retroperitoneal unicentric Castleman’s disease found 
incidentally in a patient with renal cell carcinoma.  
Case Report 
A 52 year old postmenopausal female presented to her primary care physician complaining of 
generalized abdominal tenderness and heavy vaginal bleeding for several weeks. The patient was 
given Provera 5 mg daily to control the bleeding. A computed tomography (CT) scan without 
contrast at this time showed a partially calcified right lower quadrant retroperitoneal mass of at 
least 5.2 cm concerning for malignancy, an enlarged uterus with possible leiomyoma, and a mass 
in the lower pole of the left kidney.  CT-guided biopsy of the retroperitoneal mass was non-
diagnostic. Labs at this time showed normocytic anemia with a hemoglobin of 7.8 g/dL. A 
referral to urologic oncology and gynecologic oncology was made.  
A retroperitoneal ultrasound showed a heterogeneous solid mass in the inferior left kidney. An 
endometrial biopsy showed complex endometrial hyperplasia with atypia.  A repeat CT with and 
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without contrast showed a solid enhancing mass of the inferior pole of the left kidney (5.1 x 4.4 x 
4.3 cm) concerning for renal cell carcinoma and a lipomatous mass with irregular central 
calcification in the retroperitoneum of the right lower quadrant (soft tissue mass measuring 5.4 
cm) unchanged from prior CT scan concerning for liposarcoma. Positron emission tomography 
(PET)/ CT imaging prior to surgery showed hypermetabolic activity in the retroperitoneal mass, 
mass of left kidney, thyroid, and the uterus. The centrally calcified soft tissue component of the 
retroperitoneal mass was hypermetabolic with peak standardized uptake value (SUV) of 5.1 
concerning for malignant sarcoma. Decision was made to undergo robotic-assisted total 
laparoscopic hysterectomy, bilateral salpingo-oophorectomy, excision of retroperitoneal mass, 
and partial nephrectomy of left kidney. During surgery, partial left nephrectomy was converted 
to left radical nephrectomy. The surgery was otherwise uncomplicated. Specimens obtained 
included left kidney and ureter, miscellaneous renal fragments, 10 cm retroperitoneal mass, 
uterus, bilateral fallopian tubes, bilateral ovaries, cervix, and pelvic washings. Pathology 
included: left kidney mass showing stage 1b clear cell renal cell carcinoma limited to the kidney, 
uterus showing endometrial hyperplasia with atypia with multiple leiomyomas, and the 
retroperitoneal mass was diagnosed as hyaline vascular variant Castleman disease. Patient’s post-
operative period was uncomplicated.  
 
 
 
Image 1. Gross picture of retroperitoneal mass with hyaline Castleman disease. 
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C.   D.  
Image 2. Microscopic picture of this case showing a) Depleted germinal center and expanded 
mantle zones, b) Expanded interfollicular area with hyalinized vessels, c) Regressed follicles 
with expanded interfollicular area, d) Depleted germinal center with penetrating vessels 
(“lollipop” appearance) 
 
Type of 
Castleman’s 
disease (% of 
all cases) 
Median age 
at diagnosis 
(years) 
5- year 
survival 
rate 
% Plasma cell 
variant 
subtype 
% hyaline 
vascular 
subtype 
Unicentric/ 
Localized (47- 
81) 
35 91% 9- 24% 76-91% 
Multicentric 
(19-53)           
55.5 27-90% 77% 19% 
Table 1. Comparison of Unicentric/ Localized and Multicentric Castleman’s disease3. 
Discussion 
While the etiology of Castleman’s disease is unknown, development of the disease is thought to 
be attributed to an autoimmune process, immunodeficiency, chronic low-grade inflammation, or 
lymphoid hamartomatous hyperplasia.2 Our patient diagnosed with stage 1b renal cell carcinoma 
is in a state of chronic inflammation, which we hypothesize may have contributed to her disease 
process. Our patient presented with vague symptoms which is consistent with localized, 
unicentric Castleman’s disease with hyaline-vascular variant.3 However, due to our patient’s 
unique situation of presenting with both Castleman’s disease and renal cell carcinoma, it is 
unclear which etiology was causing her presenting symptoms.  
Our patient’s repeat CT scan initially was concerning for a liposarcoma and further imaging with 
PET/CT scan was concerning for sarcoma. Common differential diagnoses for Castleman’s 
disease should include retroperitoneal sarcoma, lymphoma, desmoid tumor, carcinoid, or 
adenopathy.1,2 Therefore, sarcoma is a common misdiagnosis for Castleman’s disease and should 
be part of a differential diagnosis with retroperitoneal masses. In hyaline-vascular variant 
13
Richardson et al.: Retroperitoneal Castleman’s Disease: a case report
Published by Marshall University's Joan C. Edwards School of Medicine, 2019
disease, 10% of masses are partially calcified, which is consistent with our patient who had 
centrally calcified soft tissue mass on CT scan.2 While smaller masses may be homogeneous, 
larger masses are often heterogeneous due to central necrosis.3  PET imaging of Castleman’s 
disease often demonstrates an SUV of fluorodeoxyglucose (FDG) in a range lower than seen in 
patients with lymphoma, which may be able to help differentiate between benign Castleman’s 
disease and malignant lymphoma.4 Ngeow et al. states that FDG uptake greater than 10 SUV is 
predictive of an aggressive B-cell lineage or suggestive of more aggressive histological 
components5. Our patient had an SUV of 5.1, which is lower than this predictive value.  
Our patient was diagnosed via tissue biopsy after full surgical resection of the peritoneal mass. 
Due to the locally invasive nature of the tumor, patient’s symptoms respond well to surgical 
resection.1 Complete surgical resection of the mass is considered curative, and recurrence has 
only been described after incomplete surgical resections.6 Therefore, our patient was treated 
according to the standard of care. Five year survival rate is nearly 100% in full surgical 
resection.6 In multicentric disease, systemic chemotherapy is required and mean survival is 
fourteen to thirty months.1 Our patient will have repeat imaging with a CT of chest, abdomen, 
and pelvis three months after surgery as well as continual follow up with a medical oncologist 
regarding her renal cell carcinoma. 
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